Ascendis Pharma (ASND) Director Jean Jacques Bienaime Awarded New Warrants

What Happened

• Jean Jacques Bienaime, a director of Ascendis Pharma A/S (ASND), had a warrant for 9,160 shares cancelled (Disposition to issuer) and was concurrently awarded a new warrant covering 9,160 shares (Grant/Award) on April 14, 2026. The transactions are recorded as derivative instruments; no per-share price or cash value is reported (N/A). Net economic exposure in quantity remained the same (9,160 underlying shares), as the cancelled instrument was replaced by the new award.

Key Details

• Transaction date: April 14, 2026; Form filed: September 28, 2026 (late filing).
• Codes: D = Disposition to issuer (cancellation) of 9,160 derivative shares; A = Grant/Award of 9,160 derivative shares.
• Price/value: N/A on the Form 4 (derivative instrument/warrant).
• Vesting notes: Footnotes show vesting schedules — one set vests 25% on June 10, 2026 then in 36 equal monthly installments (F1); another vests 25% on April 14, 2027 then in 36 equal monthly installments (F3). Footnote F2 states the prior warrant (granted June 10, 2025) was cancelled and replaced as part of his board appointment.
• Shares owned after transaction: The filing shows the cancelled and replacement instruments for the same amount (9,160), so there is no reported increase in underlying count from these entries. The Form does not report a cash sale or open-market trade.
• Timeliness: The Form 4 was filed about 5.5 months after the April 14, 2026 transaction; late filings delay public disclosure of insider activity.

Context

• These were derivative transactions (warrants), not an open-market purchase or immediate sale of common stock. Warrants must vest and then be exercised to convert into common shares, so this award does not equal immediate share ownership or sale proceeds. Awards to directors are commonly part of compensation for service; they are routine but still material to track for dilution and future insider selling possibilities.